

Pharmaceutical Management Agency

# Section H Update for Hospital Pharmaceuticals

Effective 1 May 2018

Cumulative for April and May 2018



## **Contents**

Summary of decisions effective 1 May 2018 .....	3
Section H changes to Part II .....	5
Index .....	20

## Summary of decisions

EFFECTIVE 1 MAY 2018

- Ambrisentan (Volibris) tab 5 mg and 10 mg – amended restriction
- Aprepitant (Emend Tri-Pack) cap 2 x 80 mg and 1 x 125 mg – price decrease and addition of HSS
- Bosentan (Bosentan-Mylan and Mylan-Bosentan) tab 62.5 mg and 125 mg – amended restriction
- Cetomacrogol with glycerol (Pharmacy Health) crm 90% with glycerol 10%, 100 g – to be delisted 1 October 2018
- Colecalciferol (Vit.D3) cap 1.25 mg (50,000 iu) – listing new Pharmacode from 10 April 2018 and delisting existing Pharmacode 1 October 2018
- Epoprostenol (Veletri) inj 500 mcg vial and 1.5 mg vial – amended restriction
- Gabapentin (Arrow-Gabapentin, Neurontin and Nupentin) cap 100 mg, 300 mg and 400 mg – addition of note
- Glyceril trinitrate (Glytrin) oral spray, 400 mcg per dose, 200 dose – new listing
- Glyceril trinitrate (Glytrin) oral spray, 400 mcg per dose, 250 dose – to be delisted 1 November 2018
- Ibuprofen (Brufen SR) tab long-acting 800 mg – listing new Pharmacode and delisting existing Pharmacode
- Iloprost (Ventavis) nebuliser soln 10 mcg per ml, 2 ml – amended restriction
- Lamivudine (Zetlam) tab 100 mg – new listing and addition of HSS
- Lamivudine (Zeffix) tab 100 mg – to be delisted 1 July 2018
- Mebeverine hydrochloride (Colofac) tab 135 mg – listing new Pharmacode and delisting existing Pharmacode
- Multivitamins (e.g. Vitabdeck) cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg – amended restriction
- Oral feed (Sustagen Hospital Formula Active (chocolate and vanilla)) powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g can, 840 g – new listing from 1 April 2018
- Oral feed (Sustagen Hospital Formula (chocolate and vanilla)) powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g can, 840 g – to be delisted 1 June 2018
- Oseltamivir tab 75 mg – amended note
- Oxytocin (Oxytocin BNM) inj 10 iu per ml, 1 ml ampoule – HSS suspended

## Summary of decisions – effective 1 May 2018 (continued)

- Pregabalin (Pregabalin Pfizer) cap 25 mg, 75 mg, 150 mg and 300 mg – new listing, addition of note and addition HSS
- Sildenafil tab 25 mg, 50 mg and 100 mg (Vedafil), and inj 0.8 mg per ml, 12.5 ml vial – amended restriction
- Sodium chloride (Pfizer) irrigation soln 0.9%, 30 ml ampoule – price increase
- Verapamil hydrochloride (Isoptin) tab 40 mg – listing new Pharmacode and delisting existing Pharmacode
- Zanamivir (Relenza Rotadisk) powder for inhalation 5 mg – amended note
- Zinc and castor oil (healthE) oint, BP, 20 g – addition of note
- Zinc and castor oil (Boucher) oint, 500 g – new listing and addition of HSS

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Section H changes to Part II

Effective 1 May 2018

### ALIMENTARY TRACT AND METABOLISM

- 15 MEBEVERINE HYDROCHLORIDE (Pharmacode change)  
 Tab 135 mg ..... 18.00 90 Colofac  
 Note – this is a listing of new Pharmacode, 2535297; 587575 to be delisted from 1 November 2018
- 26 MULTIVITAMINS (amended restriction)  
 → Cap vitamin A 2500 u, betacarotene 3 mg, colecalfiferol 11 mcg,  
 alpha tocopherol 150 u, phytomenadione 150 mcg,  
 folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg,  
 pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg,  
 pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg,  
 zinc 7.5 mg and biotin 100 mcg *e.g. Vitabdeck*
- Restricted  
 Initiation  
 Either: **Any of the following:**  
 1 Patient has cystic fibrosis with pancreatic insufficiency; or  
 2 Patient is an infant or child with liver disease or short gut syndrome; or  
 3 **Patient has severe malabsorption syndrome.**

### CARDIOVASCULAR SYSTEM

- 47 VERAPAMIL HYDROCHLORIDE (Pharmacode change)  
 Tab 40 mg ..... 7.01 100 Isoptin  
 Note – This is a listing of new Pharmacode, 2535327; 253499 to be delisted from 1 November 2018.
- 51 GLYCERYL TRINITRATE (pack size change)  
 Oral spray, 400 mcg per dose..... 4.45 200 dose Glytrin  
 Note – this is the listing of the 200 dose pack; the 250 dose pack will be delisted from 1 November 2018.
- 52 AMBRISENTAN (amended restriction)  
 → Tab 5 mg ..... 4,585.00 30 Volibris  
 → Tab 10 mg ..... 4,585.00 30 Volibris
- Restricted  
 Initiation  
 Either:  
 1 For use in patients with a valid Special Authority approval for ambrisentan **by the in Ppulmonary Aarterial Hhypertension Panel;** or  
 2 In-hospital stabilisations in emergency situations.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 May 2018 (continued)

52	BOSENTAN (amended restriction)			
	→ Tab 62.5 mg – 1% DV Jan-16 to 2018 .....	401.79	60	Bosentan-Mylan
		375.00	56	<b>Mylan-Bosentan</b>
	→ Tab 125 mg – 1% DV Jan-16 to 2018 .....	401.79	60	Bosentan-Mylan
		375.00	56	<b>Mylan-Bosentan</b>

Restricted

Initiation – **Pulmonary arterial hypertension**

**Re-assessment required after 6 months**

Either:

1 All of the following:

- 1.1 Patient has pulmonary arterial hypertension (PAH); and
- 1.2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
- 1.3 PAH is at NYHA/WHO functional class II, III, or IV; and
- 1.4 Any of the following:

1.4.1 Both:

1.4.1.1 Bosentan is to be used as PAH monotherapy; and

1.4.1.2 Either:

- 1.4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
- 1.4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or

1.4.2 Both:

1.4.2.1 Bosentan is to be used as PAH dual therapy; and

1.4.2.2 Either:

- 1.4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
- 1.4.2.2.2 Patient deteriorated while on a PAH monotherapy; or

1.4.3 Both:

1.4.3.1 Bosentan is to be used as PAH triple therapy; and

1.4.3.2 Any of the following:

- 1.4.3.2.1 Patient is on the lung transplant list; or
- 1.4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
- 1.4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
- 1.4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

2 In-hospital stabilisation in emergency situations.

Continuation – **Pulmonary arterial hypertension**

**Re-assessment required after 6 months**

Any of the following:

1 Both:

- 1.1 Bosentan is to be used as PAH monotherapy; and
- 1.2 Patient is stable or has improved while on bosentan; or

2 Both:

- 2.1 Bosentan is to be used as PAH dual therapy; and
- 2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or

*continued...*

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

**Changes to Section H Part II – effective 1 May 2018 (continued)**

*continued...*

**3 Both:**

**3.1 Bosentan is to be used as PAH triple therapy; and**

**3.2 Any of the following:**

**3.2.1 Patient is on the lung transplant list; or**

**3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or**

**3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or**

**3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.**

- 1 For use in patients with a valid Special Authority approval for bosentan in pulmonary arterial hypertension; or  
 2 In hospital stabilisation in emergency situations.

53

SILDENAFIL (amended restriction – affected criteria only shown)

→ Tab 25 mg – <b>1% DV Sep-15 to 2018</b> .....	0.75	4	<b>Vedafil</b>
→ Tab 50 mg – <b>1% DV Sep-15 to 2018</b> .....	0.75	4	<b>Vedafil</b>
→ Tab 100 mg – <b>1% DV Sep-15 to 2018</b> .....	2.75	4	<b>Vedafil</b>
→ Inj 0.8 mg per ml, 12.5 ml vial			

Restricted

Initiation – tablets **Raynaud's Phenomenon\***

**All of the following:**

**1 Patient has Raynaud's phenomenon; and**

**2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and**

**3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and**

**4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).**

Initiation – tablets (Pulmonary arterial hypertension)

Any of the following:

**1 All of the following:**

**1.1 Patient has pulmonary arterial hypertension (PAH)\*; and**

**1.2 Any of the following:**

**1.2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or**

**1.2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or**

**1.2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and**

**1.3 Any of the following:**

**1.3.1 PAH is in NYHA/WHO functional class II; or**

**1.3.2 PAH is in NYHA/WHO functional class III; or**

**1.3.3 PAH is in NYHA/WHO functional class IV; and**

**1.4 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and**

**1.5 Either:**

**1.5.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or**

**1.5.2 Patient is peri Fontan repair; and**

**1.6 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm<sup>-5</sup>); or**

**2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or**

**3 In-hospital stabilisation in emergency situations.**

Initiation – tablets (other conditions)

Any of the following:

*continued...*

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 May 2018 (continued)**

*continued...*

- 1 For use in weaning patients from inhaled nitric oxide; or
- 2 For perioperative use in cardiac surgery patients; or
- 3 For use in intensive care as an alternative to nitric oxide.

Any of the following:

- 1 For use in patients with a valid Special Authority approval for sildenafil in pulmonary arterial hypertension; or
- 2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
- 3 For use in weaning patients from inhaled nitric oxide; or
- 4 For perioperative use in cardiac surgery patients; or
- 5 For use in intensive care as an alternative to nitric oxide; or
- 6 In-hospital stabilisation in emergency situations; or

7 All of the following:

- 7.1 Patient has Raynaud's phenomenon; and
- 7.2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 7.3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
- 7.4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

53 EPOPROSTENOL (amended restriction)

➔ Inj 500 mcg vial .....	36.61	1	Veletri
➔ Inj 1.5 mg vial .....	73.21	1	Veletri

Restricted

Initiation

Either:

- 1 For use in patients with a valid Special Authority approval for epoprostenol **by the in Ppulmonary Aarterial Hhypertension Panel**; or
- 2 In-hospital stabilisations in emergency situations.

53 ILOPROST (amended restriction)

➔ Nebuliser soln 10 mcg per ml, 2 ml .....	1,185.00	30	Ventavis
--	----------	----	----------

Restricted

Initiation

Any of the following:

- 1 For use in patients with a valid Special Authority approval for iloprost **by the in Ppulmonary Aarterial Hhypertension Panel**; or
- 2 For diagnostic use in catheter laboratories; or
- 3 For use following mitral or tricuspid valve surgery; or
- 4 In-hospital hospital stabilisation in emergency situations.

**DERMATOLOGICALS**

56 ZINC AND CASTOR OIL (addition of note)

Oint, BP – 1% DV Nov-17 to 2020 .....	1.26	20 g	healthE
---------------------------------------	------	------	---------

**Note – DV limit applies to the pack sizes of 30 g or less.**

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.



	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 May 2018 (continued)

56	ZINC AND CASTOR OIL (new listing) Oint – <b>1% DV Jul-18 to 2020</b> .....	4.25	500 g	<b>Boucher</b>
	Note – DV limit applies to pack sizes of greater than 30 g.			
57	CETOMACROGOL WITH GLYCEROL (delisting) Crm 90% with glycerol 10% .....	2.00 2.10	100 g	Pharmacy Health Pharmacy Health
	Note – Pharmacy Health crm 90% with glycerol 10% 100 g to be delisted from 1 October 2018.			

### GENITO-URINARY SYSTEM

63	OXYTOCIN (HSS suspended) Inj 10 iu per ml, 1 ml ampoule – <b>1% DV Nov-15 to 2018 30 Apr 18</b> .....	5.03	5	Oxytocin BNM
----	---	------	---	--------------

### INFECTIONS

93	LAMIVUDINE (brand change) Tab 100 mg – <b>1% DV Jul-18 to 2020</b> .....	4.20	28	<b>Zetlam</b>
	Note – Zeffix tab 100 mg to be delisted from 1 July 2018.			
96	OSELTAMIVIR (amended note) Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community under Rule 8 of Section H for a new course is not permitted. <b>Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.</b> → Tab 75 mg → Powder for oral suspension 6 mg per ml			
96	ZANAMIVIR (amended note) Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community under Rule 8 of Section H for a new course is not permitted. <b>Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.</b> → Powder for inhalation 5 mg .....	37.38	20 dose	Relenza Rotadisk

### MUSCULOSKELETAL SYSTEM

107	IBUPROFEN (Pharmacode change) Tab long-acting 800 mg – <b>1% DV Jul-15 to 2018</b> .....	7.99	30	<b>Brufen SR</b>
	Note – this is a new listing of a new Pharmacode, 2534320; 2255499 to be delisted from 1 November 2018.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 May 2018 (continued)**

**NERVOUS SYSTEM**

118	GABAPENTIN (addition of note) <b>Note – Gabapentin not to be given in combination with pregabalin.</b> → Cap 100 mg.....	7.16	100	Arrow-Gabapentin Neurontin Nupentin
	→ Cap 300 mg.....	11.00	100	Arrow-Gabapentin Neurontin Nupentin
	→ Cap 400 mg.....	13.75	100	Arrow-Gabapentin Neurontin Nupentin
120	PREGABALIN (new listing) Note – Pregabalin not to be given in combination with gabapentin. Cap 25 mg – 1% DV Jul-18 to 2021.....	2.25	56	<b>Pregabalin Pfizer</b>
	Cap 75 mg – 1% DV Jul-18 to 2021.....	2.65	56	<b>Pregabalin Pfizer</b>
	Cap 150 mg – 1% DV Jul-18 to 2021.....	4.01	56	<b>Pregabalin Pfizer</b>
	Cap 300 mg – 1% DV Jul-18 to 2021.....	7.38	56	<b>Pregabalin Pfizer</b>
122	APREPITANT (↓ price and addition of HSS) → Cap 2 × 80 mg and 1 × 125 mg – 1% DV Jul-18 to 2021 ....	84.00	3	<b>Emend Tri-Pack</b>

**VARIOUS**

209	SODIUM CHLORIDE (↑ price) Irrigation soln 0.9%, 30 ml ampoule.....	27.00	30	Pfizer
-----	---	-------	----	--------

**Effective 10 April 2018**

**ALIMENTARY TRACT AND METABOLISM**

28	COLECALCIFEROL (Pharmacode change) Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020.....	2.50	12	<b>Vit.D3</b>
	Note – this is a listing of a new blister pack Pharmacode, 2523590. The bottle pack will be delisted from 1 October 2018, Pharmacode, 2446154.			

**Effective 1 April 2018**

**ALIMENTARY TRACT AND METABOLISM**

20	DOCUSATE SODIUM WITH SENNOSIDES (↓ price and addition of HSS) Tab 50 mg with sennosides 8 mg – 1% DV Jun-18 to 2021 .....	3.10	200	<b>Laxsol</b>
23	LEVOCARNITINE (new listing) Oral soln 1,000 mg per 10 ml			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 April 2018 (continued)

23	LEVOCARNITINE (delisting) Oral soln 1,100 mg per 15 ml Note – levocarnitine oral soln 1,100 mg per 15 ml to be delisted from 1 October 2018.		
24	FERROUS FUMARATE WITH FOLIC ACID (↓ price and addition of HSS) Tab 310 mg (100 mg elemental) with folic acid 350 mcg – <b>1% DV Jun-18 to 2021</b> .....	4.68	60 <b>Ferro-F-Tabs</b>
24	FERROUS SULPHATE (addition of HSS) Tab long-acting 325 mg (105 mg elemental) – <b>1% DV Jun-18 to 2021</b> .....	2.06	30 <b>Ferrograd</b>

### BLOOD AND BLOOD FORMING ORGANS

38	COMPOUND ELECTROLYTES (new listing) Inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, 500 ml bag – <b>1% DV Jun-18 to 2021</b> .....	44.10	18 <b>Plasma-Lyte 148</b>
	Inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	27.24	12 <b>Plasma-Lyte 148</b>
38	COMPOUND ELECTROLYTES (delisting) Inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, bag .....	2.40	1,000 ml Baxter
		5.00	500 ml Baxter
	Note – Baxter inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, bag, 500 ml and 1,000 ml pack to be delisted from 1 June 2018.		
38	COMPOUND ELECTROLYTES WITH GLUCOSE (new listing) Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	211.92	12 <b>Plasma-Lyte 148 &amp; 5% glucose</b>
38	COMPOUND ELECTROLYTES WITH GLUCOSE (delisting) Inj glucose 50 g with 140 mmol/l sodium, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, bag .....	7.00	1,000 ml Baxter
	Note – Baxter Inj glucose 50 g with 140 mmol/l sodium, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, bag, 1,000 ml pack to be delisted from 1 June 2018.		

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 April 2018 (continued)

38	COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION] (new listing) Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag – <b>1% DV Jun-18 to 2021</b> .....	23.40	18	Baxter
	Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	15.72	12	Baxter
38	COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION] (delisting) Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, bag.....	1.77	500 ml	Baxter
		1.80	1,000 ml	Baxter
	Note – Baxter inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, bag, 500 ml and 1,000 ml pack to be delisted from 1 June 2018.			
38	COMPOUND SODIUM LACTATE WITH GLUCOSE (delisting) Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l and glucose 5%, bag.....	5.38	1,000 ml	Baxter
	Note – Baxter inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l and glucose 5%, bag, 1,000 ml pack to be delisted from 1 June 2018.			
38	GLUCOSE [DEXTROSE] (new listing) Inj 5%, 50 ml bag – <b>1% DV Jun-18 to 2021</b> .....	143.40	60	<b>Baxter Glucose 5%</b>
	Inj 10%, 500 ml bag – <b>1% DV Jun-18 to 2021</b> .....	109.98	18	<b>Baxter Glucose 10%</b>
	Inj 10%, 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	111.96	12	<b>Baxter Glucose 10%</b>
	Inj 50%, 500 ml bag – <b>1% DV Jun-18 to 2021</b> .....	337.32	18	<b>Baxter Glucose 50%</b>
38	GLUCOSE [DEXTROSE] (delisting) Inj 5%, bag .....	2.87	50 ml	Baxter
	Inj 10%, bag .....	6.11	500 ml	Baxter
		9.33	1,000 ml	Baxter
	Inj 50%, bag .....	18.74	500 ml	Baxter
	Inj 70%, 500 ml bag Inj 70%, 1,000 ml bag			
	Note – Baxter inj 5%, bag, 50 ml; inj 10%, bag, 500 ml and 1,000 ml; inj 50%, bag 500 ml and inj 70%, 500 ml and 1,000 ml bag pack to be delisted from 1 June 2018.			
38	GLUCOSE WITH POTASSIUM CHLORIDE (new listing) Inj 10% glucose with 20 mmol/l potassium chloride, 500 ml bag			
38	GLUCOSE WITH POTASSIUM CHLORIDE (delisting) Inj 5% glucose with 20 mmol/l potassium chloride, bag .....	12.09	1,000 ml	Baxter
	Inj 5% glucose with 30 mmol/l potassium chloride, 1,000 ml bag Inj 10% glucose with 10 mmol/l potassium chloride, 500 ml bag			
	Note – Baxter inj 5% glucose with 20 mmol/l potassium chloride, bag, 1,000 ml; inj 5% glucose with 30 mmol/l potassium chloride, 1,000 ml bag and inj 10% glucose with 10 mmol/l potassium chloride, 500 ml bag to be delisted from 1 June 2018.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 April 2018 (continued)

39	GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE (new listing)			
	Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, 1,000 ml bag			
	– <b>1% DV Jun-18 to 2021</b> .....	203.40	12	<b>Baxter</b>
	Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 1,000 ml bag			
	– <b>1% DV Jun-18 to 2021</b> .....	159.96	12	<b>Baxter</b>
	Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, 1,000 ml bag			
	– <b>1% DV Jun-18 to 2021</b> .....	282.72	12	<b>Baxter</b>
39	GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE (delisting)			
	Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, bag .....	3.45	500 ml	Baxter
		8.31	1,000 ml	Baxter
	Inj 4% glucose with potassium chloride 30 mmol/l and sodium chloride 0.18%, bag .....	10.74	1,000 ml	Baxter
	Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, bag .....	8.29	1,000 ml	Baxter
	Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, bag .....	12.50	1,000 ml	Baxter
	Note – Baxter inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, bag, 500 ml and 1,000 ml; inj 4% glucose with potassium chloride 30 mmol/l and sodium chloride 0.18%, bag, 1,000 ml; inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, bag, 1,000 ml and inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, bag, 1,000 ml pack to be delisted 1 June 2018.			
39	GLUCOSE WITH SODIUM CHLORIDE (new listing)			
	Inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	163.32	12	<b>Baxter</b>
	Inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	163.20	12	<b>Baxter</b>
	Inj 5% glucose and sodium chloride 0.9%, 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	173.40	12	<b>Baxter</b>
	Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag			
39	GLUCOSE WITH SODIUM CHLORIDE (delisting)			
	Inj glucose 2.5% with sodium chloride 0.45%, bag .....	8.12	500 ml	Baxter
	Inj glucose 5% with sodium chloride 0.45%, bag .....	5.80	1,000 ml	Baxter
	Inj glucose 5% with sodium chloride 0.9%, bag .....	8.92	1,000 ml	Baxter
	Inj glucose 5% with sodium chloride 0.2%, 500 ml bag			
	Note – Baxter inj glucose 2.5% with sodium chloride 0.45%, bag, 500 ml; inj glucose 5% with sodium chloride 0.45%, bag, 1,000 ml; inj glucose 5% with sodium chloride 0.9%, bag, 1,000 ml and inj glucose 5% with sodium chloride 0.2%, 500 ml bag pack to be delisted from 1 June 2018.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 April 2018 (continued)

39	POTASSIUM CHLORIDE WITH SODIUM CHLORIDE (new listing) Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag – <b>1% DV Jun-18 to 2021</b> .....	476.64	48	<b>Baxter</b>
	Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	163.08	12	<b>Baxter</b>
	Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag – <b>1% DV Jun-18 to 2021</b> .....	772.32	48	<b>Baxter</b>
	Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	253.32	12	<b>Baxter</b>
39	POTASSIUM CHLORIDE WITH SODIUM CHLORIDE (delisting) Inj 20 mmol/l potassium chloride with 0.9% sodium chloride, bag.....	7.66	1,000 ml	Baxter
	Inj 30 mmol/l potassium chloride with 0.9% sodium chloride, bag.....	9.40	1,000 ml	Baxter
	Inj 40 mmol/l potassium chloride with 0.9% sodium chloride, bag.....	12.26	1,000 ml	Baxter
	Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag Note – Baxter inj 20 mmol/l potassium chloride with 0.9% sodium chloride, bag, 1,000 ml; inj 30 mmol/l potassium chloride with 0.9% sodium chloride, bag, 1,000 ml; inj 40 mmol/l potassium chloride with 0.9% sodium chloride, bag, 1,000 ml; inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag and inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag to be delisted from 1 June 2018.			
39	RINGER'S SOLUTION (new listing) Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, 1,000 ml bag			
39	RINGER'S SOLUTION (delisting) Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, bag .....	8.69	1,000 ml	Baxter
	Note – Baxter inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, bag, 1,000 ml pack to be delisted from 1 June 2018.			
41	GELATINE, SUCCINYLATED († price and addition of HSS) Inj 4%, 500 ml bag – <b>1% DV Jun-18 to 2021</b> .....	120.00	10	<b>Gelofusine</b>
41	HYDROXYETHYL STARCH 130/0.4 WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE AND SODIUM CHLORIDE (delisting) Inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag .....	198.00	20	Volulyte 6%
	Note - Volulyte 6% inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag to be delisted from 1 June 2018.			
41	HYDROXYETHYL STARCH 130/0.4 WITH SODIUM CHLORIDE (delisting) Inj 6% with sodium chloride 0.9%, 500 ml bag.....	198.00	20	Voluven
	Note – Voluven inj 6% with sodium chloride 0.9%, 500 ml bag to be delisted from 1 June 2018.			

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 April 2018 (continued)

### CARDIOVASCULAR SYSTEM

46	PROPRANOLOL (delisting)			
	Tab 10 mg .....	3.65	100	Apo-Propranolol
	Tab 40 mg .....	4.65	100	Apo-Propranolol
	Note – Apo-Propranolol tab 10 mg and 40 mg to be delisted from 1 July 2018. This delist only applies to Pharmacodes 2400790 and 2400804.			
47	DILTIAZEM HYDROCHLORIDE (delisting)			
	Cap long-acting 120 mg .....	1.91	30	Cardizem CD
	Cap long-acting 180 mg .....	7.56	30	Cardizem CD
	Cap long-acting 240 mg .....	10.22	30	Cardizem CD
	Note – Cardizem CD cap long-acting 120 mg, 180 mg and 240 mg to be delisted from 1 June 2018			
48	MANNITOL (new listing)			
	Inj 10%, 1,000 ml bag – <b>1% DV Jun-18 to 2021</b> .....	747.24	12	<b>Baxter</b>
	Inj 20%, 500 ml bag – <b>1% DV Jun-18 to 2021</b> .....	1,096.92	18	<b>Baxter</b>
48	MANNITOL (delisting)			
	Inj 10%, 1,000 ml bag .....	24.85	1,000 ml	Baxter
	Inj 20%, 500 ml bag .....	23.08	500 ml	Baxter
	Note – Baxter inj 10%, 1,000 ml bag and inj 20%, 500 ml bag to be delisted from 1 June 2018.			

### DERMATOLOGICALS

56	TRETINOIN (new listing)			
	Crm 0.05% – <b>1% DV Jun-18 to 2021</b> .....	13.90	50 g	<b>ReTrieve</b>

### HORMONE PREPARATIONS

68	PREDNISOLONE (↓ price and addition of HSS)			
	Oral liq 5 mg per ml – <b>1% DV Jun-18 to 2021</b> .....	6.00	30 ml	<b>Redipred</b>

### INFECTIONS

77	MEROPENEM (↑ price)			
	→ Inj 500 mg vial .....	102.00	10	DBL Meropenem
	→ Inj 1 g vial .....	159.00	10	DBL Meropenem

### MUSCULOSKELETAL SYSTEM

106	ATRACURIUM BESYLATE (addition of HSS)			
	Inj 10 mg per ml, 2.5 ml ampoule – <b>1% DV Jun-18 to 2021</b> .....	10.00	5	<b>Tracrium</b>
	Inj 10 mg per ml, 5 ml ampoule – <b>1% DV Jun-18 to 2021</b> .....	12.50	5	<b>Tracrium</b>
106	ORPHENADRINE CITRATE (new listing)			
	Tab 100 mg – <b>1% DV Jun-18 to 2021</b> .....	18.54	100	<b>Norflex</b>

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 April 2018 (continued)

### NERVOUS SYSTEM

113	PARACETAMOL (delisting) Tab soluble 500 mg.....	1.60	20	Paragesic Soluble
	Note – Paragesic Soluble tab soluble 500 mg to be delisted from 1 July 2018.			
116	PETHIDINE HYDROCHLORIDE (delisting) Tab 100 mg – 1% DV Nov-15 to 2018 .....	6.25	10	PSM
	Note – PSM tab 100 mg to be delisted from 1 July 2018.			
117	ESCITALOPRAM (amended brand name) Tab 10 mg – 1% DV Dec-17 to 2020 .....	1.11	28	App-Escitalopram- Apotex
	Tab 20 mg – 1% DV Dec-17 to 2020 .....	1.90	28	App-Escitalopram- Apotex
123	DROPERIDOL (new listing) Inj 2.5 mg per ml, 1 ml ampoule – 1% DV Jun-18 to 2019.....	35.00	10	Droperidol Panpharma
127	CLONAZEPAM (↓ price and addition of HSS) Tab 500 mcg – 1% DV Jun-18 to 2021 .....	5.64	100	Paxam
	Tab 2 mg – 1% DV Jun-18 to 2021 .....	10.78	100	Paxam

### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

137	CYTARABINE (↑ price) Inj 20 mg per ml, 5 ml vial .....	400.00	5	Pfizer
137	CYTARABINE (delisting) Inj 100 mg per ml, 10 ml vial .....	8.83	1	Pfizer
	Note – Pfizer inj 100 mg per ml, 10 ml vial delisted from 1 April 2018.			
136	DAUNORUBICIN (↑ price) Inj 2 mg per ml, 10 ml vial .....	130.00	1	Pfizer



	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 April 2018 (continued)**

**RESPIRATORY SYSTEM AND ALLERGIES**

193	MONTELUKAST (restriction removed)			
	Tab 4 mg – <b>1% DV Jan-17 to 2019</b> .....	5.25	28	<b>Apo-Montelukast</b>
	Tab 5 mg – <b>1% DV Jan-17 to 2019</b> .....	5.50	28	<b>Apo-Montelukast</b>
	Tab 10 mg – <b>1% DV Jan-17 to 2019</b> .....	5.65	28	<b>Apo-Montelukast</b>
	Restricted			
	Initiation — Pre-school wheeze			
	Both:			
	1 – To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and			
	2 – The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.			
	Initiation — Exercise-induced asthma			
	All of the following:			
	1 – Patient has been trialed with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and			
	2 – Patient continues to receive optimal inhaled corticosteroid therapy; and			
	3 – Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.			
	Initiation — Aspirin desensitisation			
	Clinical immunologist or allergist			
	All of the following:			
	1 – Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and			
	2 – Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and			
	3 – Nasal polyposis, confirmed radiologically or surgically; and			
	4 – Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.			

**SENSORY ORGANS**

196	CIPROFLOXACIN (new listing)			
	Eye drops 0.3% – <b>1% DV Jun-18 to 2020</b> .....	9.99	5 ml	<b>Ciprofloxacin Teva</b>
198	PREDNISOLONE ACETATE (new listing)			
	Eye drops 1% .....	7.00	5 ml	Pred Forte

**VARIOUS**

208	CHLORHEXIDINE (delisting)			
	Irrigation soln 0.02%, bottle .....	6.20	100 ml	Baxter
	Irrigation soln 0.05%, bottle .....	7.37	500 ml	Baxter
		7.83	100 ml	Baxter
	Irrigation soln 0.1%, bottle .....	8.71	100 ml	Baxter
	Irrigation soln 0.02%, 500 ml bottle			
	Irrigation soln 0.1%, 30 ml ampoule			
	Note – Baxter irrigation soln 0.02%, bottle, 100 ml; irrigation soln 0.05%, bottle, 100 ml and 500 ml; irrigation soln 0.1%, bottle, 100 ml; irrigation soln 0.02%, 500 ml bottle and irrigation soln 0.1%, 30 ml ampoule pack to be delisted from 1 June 2018.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

### Changes to Section H Part II – effective 1 April 2018 (continued)

209	SODIUM CHLORIDE (new listing) Irrigation soln 0.9%, 1,000 ml bottle – 1% DV Jun-18 to 2021.....	14.90	10	<b>Baxter Sodium Chloride 0.9%</b>
209	SODIUM CHLORIDE (delisting) Irrigation soln 0.9%, bottle..... Note – Baxter irrigation soln 0.9%, bottle, 1,000 ml pack to be delisted 1 June 2018.	6.59	1,000 ml	Baxter
209	WATER (new listing) Irrigation soln, 1,000 ml bottle – 1% DV Jun-18 to 2021.....	17.30	10	<b>Baxter Water for Irrigation</b>
209	WATER (delisting) Irrigation soln, bottle..... Note – Baxter Irrigation soln, bottle, 1,000 ml to be delisted from 1 June 2018.	6.58	1,000 ml	Baxter

### SPECIAL FOODS

218	AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (new listing) → Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per 100 g, 109 g pot			<i>e.g. PKU Lophlex Sensation 20 (berries)</i>
228	ORAL FEED (new listing) → Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can.....	26.00	840 g	Sustagen Hospital Formula Active (Chocolate) Sustagen Hospital Formula Active (Vanilla)
Note: Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer's surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.				
228	ORAL FEED (↑ price and delisting) → Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can.....	26.00	840 g	Sustagen Hospital Formula (Chocolate) Sustagen Hospital Formula (Vanilla)
Note: Sustagen Hospital Formula (Chocolate and Vanilla) powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can, 840 g to be delisted from 1 June 2018.				

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

**Changes to Section H Part II – effective 1 April 2018 (continued)**

**VACCINES**

237	VARICELLA ZOSTER VACCINE [SHINGLES VACCINE]			
	→ Varicella zoster virus (Oka strain) live attenuated vaccine [shingles vaccine] .....	0.00	1	Zostavax
			10	Zostavax

Restricted

Initiation – people aged 65 years

*Therapy limited to 1 dose*

One dose for all people aged 65 years.

Initiation – people aged between 66 and 80 years

*Therapy limited to 1 dose*

One dose for all people aged between 66 and 80 years inclusive from 1 April 2018 and 31 March 2020.

# Index

## Pharmaceuticals and brands

<b>A</b>	
Ambrisentan .....	5
Amino acid formula (without phenylalanine).....	18
Apo-Escitalopram.....	16
Apo-Montelukast.....	17
Apo-Propranolol.....	15
Aprepitant .....	10
Arrow-Gabapentin.....	10
Atracurium besylate .....	15
<b>B</b>	
Baxter Glucose 5%.....	12
Baxter Glucose 10%.....	12
Baxter Glucose 50%.....	12
Baxter Sodium Chloride 0.9%.....	18
Baxter Water for Irrigation.....	18
Bosentan .....	6
Bosentan-Mylan.....	6
Brufen SR.....	9
<b>C</b>	
Cardizem CD.....	15
Cetomacrogol with glycerol.....	9
Chlorhexidine .....	17
Ciprofloxacin.....	17
Ciprofloxacin Teva.....	17
Clonazepam.....	16
Colecalciferol.....	10
Colofac .....	5
Compound electrolytes.....	11
Compound electrolytes with glucose .....	11
Compound sodium lactate [Hartmann's solution]..	12
Compound sodium lactate with glucose .....	12
Cytarabine .....	16
<b>D</b>	
Daunorubicin .....	16
DBL Meropenem .....	15
Dextrose .....	12
Diltiazem hydrochloride.....	15
Docusate sodium with sennosides .....	10
Droperidol.....	16
Droperidol Panpharma.....	16
<b>E</b>	
Emend Tri-Pack .....	10
Epoprostenol.....	8
Escitalopram.....	16
Escitalopram-Apotex .....	16
<b>F</b>	
Ferro-F-Tabs.....	11
Ferrograd .....	11
Ferrous fumarate with folic acid.....	11
Ferrous sulphate .....	11
<b>G</b>	
Gabapentin .....	10
Gelatine, succinylated .....	14
Gelofusine.....	14
Glucose [dextrose].....	12
Glucose with potassium chloride.....	12
Glucose with potassium chloride and sodium chloride .....	13
Glucose with sodium chloride.....	13
Glyceryl trinitrate .....	5
Glytrin.....	5
<b>H</b>	
Hartmann's solution.....	12
Hydroxyethyl starch 130/0.4 with magnesium chloride, potassium chloride, sodium acetate and sodium chloride.....	14
Hydroxyethyl starch 130/0.4 with sodium chloride .....	14
<b>I</b>	
Ibuprofen .....	9
Iloprost .....	8
Isoptin .....	5
<b>L</b>	
Lamivudine .....	9
Laxsol.....	10
Levocarnitine .....	10, 11
<b>M</b>	
Mannitol.....	15
Mebeverine hydrochloride .....	5
Meropenem .....	15
Montelukast.....	17
Multivitamins .....	5
Mylan-Bosentan.....	6
<b>N</b>	
Neurontin .....	10
Norflex.....	15
Nupentin .....	10
<b>O</b>	
Oral feed.....	18
Orphenadrine citrate.....	15
Oseltamivir.....	9
Oxytocin .....	9
Oxytocin BNM.....	9
<b>P</b>	
Paracetamol.....	16
Paragesic Soluble .....	16
Paxam .....	16
Pethidine hydrochloride.....	16
PKU Lophlex Sensation 20 (berries) .....	18
Plasma-Lyte 148.....	11
Plasma-Lyte 148 & 5% glucose.....	11

# Index

## Pharmaceuticals and brands

Potassium chloride with sodium chloride.....	14	<b>T</b>	
Pred Forte.....	17	Tracrium.....	15
Prednisolone.....	15	Tretinoin.....	15
Prednisolone acetate.....	17	<b>V</b>	
Pregabalin.....	10	Varicella zoster vaccine [shingles vaccine].....	19
Pregabalin Pfizer.....	10	Vedafil.....	7
Propranolol.....	15	Veletri.....	8
<b>R</b>		Ventavis.....	8
Redipred.....	15	Verapamil hydrochloride.....	5
Relenza Rotadisk.....	9	Vitabdeck.....	5
ReTrieve.....	15	Vit.D3.....	10
Ringer's solution.....	14	Volibris.....	5
<b>S</b>		Volulyte 6%.....	14
Shingles vaccine.....	19	Voluven.....	14
Sildenafil.....	7	<b>W</b>	
Sodium chloride.....	10, 18	Water.....	18
Sustagen Hospital Formula Active (Chocolate)....	18	<b>Z</b>	
Sustagen Hospital Formula Active (Vanilla).....	18	Zanamivir.....	9
Sustagen Hospital Formula (Chocolate).....	18	Zetiam.....	9
Sustagen Hospital Formula (Vanilla).....	18	Zinc and castor oil.....	8, 9
		Zostavax.....	19



**Email:** [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

**www.pharmac.govt.nz/medicines/hospital-pharmaceuticals**

**Pharmaceutical Management Agency**

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand  
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

ISSN 1179-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand